Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

作者：Kenneth H. Mayer, Jean‐Michel Molina, Melanie Thompson, Peter L. Anderson, Karam Mounzer, Joss J De Wet, Edwin DeJesus, Heiko Jessen, Robert M. Grant, Peter Ruane, Pamela Wong, Ramin Ebrahimi, Lijie Zhong, Anita Mathias, Christian Callebaut, Sean E Collins, Moupali Das, Scott McCallister, Diana M. Brainard, Cynthia Brinson, Amanda Clarke, Pep Coll, Frank A. Post, C. Bradley Hare · 发表于：The Lancet · 年份：2020 · DOI：10.1016/s0140-6736(20)31065-5 · 被引用次数：431 · 研究领域：HIV/AIDS Research and Interventions、HIV/AIDS drug development and treatment、HIV-related health complications and treatments